Aprea Therapeutics, Inc. (APRE) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-01

Key Insights

Insider Richard Peters acquired pre-funded warrants and common warrants to purchase a total of 247,830 shares of Aprea Therapeutics, Inc. (APRE) common stock at discounted prices in a private placement.
The pre-funded warrants are immediately exercisable, subject to a beneficial ownership limitation, while the common warrants will expire on the earlier of December 31, 2029 or 30 days after the pre-funded warrants are exercised.
The insider acquisition suggests Peters' confidence in Aprea Therapeutics' future prospects and could signal potential upside for the stock if the warrants are exercised.

Want the newest filings?

This analysis covers the filing from 2026-04-01. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-04-01

The reporting person, John P. Hamill, who is the Senior VP, CFO, and Principal Financial and Accounting Officer of Aprea Therapeutics, Inc. (APRE), acquired pre-funded warrants and accompanying common warrants to purchase a total of 61,956 shares of the company's common stock on March 31, 2026.
The pre-funded warrants are immediately exercisable, subject to a beneficial ownership limitation of 4.99% of the company's outstanding shares or 9.99% of the company's voting power.
The common warrants are also immediately exercisable, subject to the same beneficial ownership limitation, and will expire on the earlier of December 31, 2029, or 30 days after the pre-funded warrants are exercised, proportional to the amount of such exercise.

Other reports for Aprea Therapeutics, Inc.

Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.